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Background: It has recently been reported that the extracts of green tea polyphenol have cancer preventive
effects. In this study, we investigated the effect of the natural composition from green tea leaves Catechins on
acute promyelocytic leukemia (APL).
Methods: In vitro, APL cell lines NB4, retinoic acid-resistant NB4-R1 and NB4-R2 were treated with different concentrations
of Catechins. Cell viability and cell apoptosis were analyzed using MTT assay and flow cytometric assay, respectively.
Expression of proteins related to apoptosis and PML-RARα oncoprotein were assessed by Western blot. In vivo
anti-tumor activity of Catechins was examined in nude mice xenografted with NB4 cells and in situ cell apoptosis
was detected by terminal deoxytransferase-catalyzed DNA nick-end labeling assay.
Results: Catechins at micromolar concentration levels significantly inhibited APL cell proliferation and induced cell
apoptosis, in association with mitochondria damage, ROS production and caspase activation. The anti-apoptotic
Bcl-2 family member Bcl-xL was down regulated, with pro-apoptotic member Bax remaining unchanged. Moreover,
Catechins induced the degradation of PML-RARα oncoprotein. Catechins-mediated apoptotic effect was also observed
in primary APL cells without affecting normal hematopoietic progenitor cells. In the murine xenograft model, Catechins
remarkably inhibited tumor growth and induced in situ leukemic cell apoptosis.
Conclusions: Catechins might be a potential candidate for APL treatment by activating intrinsic apoptotic pathway
and targeting PML-RARα oncoprotein.
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Acute promyelocytic leukemia (APL) accounts for ap-
proximately 10% of all acute myeloid leukemias and is
characterized by a specific chromosomal translocation t
(15;17), resulting in the fusion of promyelocytic leukemia
(PML) gene to retinoic acid receptor (RARα) gene. The
expression of PML-RARα chimeric protein plays a central
role in leukemogenesis, including arrest of differentiation* Correspondence: zhao.weili@yahoo.com
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unless otherwise stated.and deregulation of apoptosis [1,2]. The currently used
agents all-trans retinoic acid (ATRA) and arsenic trioxide
(As2O3) directly target PML-RARα oncoprotein and
dramatically improve the clinical outcome of APL pa-
tients [3-13]. This greatly encourages further discovery
of potential molecular target-based agents, particularly
nature products, on APL treatment.
Epidemiologic studies have already shown that green
tea consumption is beneficial to health and can reduce
the incidence of cancer [14]. Recently, green tea products
have attracted more attention because of their anti-cancer
effects revealed in experimental tumor models [15-32].
Catechins is the main component extracted from the
green tea leaves, including epipallocatechin gallate
(EGCG), epicatechin gallate (ECG), epigallocatechinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to be inexpensive, safe, and can be administrated orally.
Therefore, whether Catechins possesses anti-leukemia
capability is of great interest to leukemia treatment.
In this study, we assessed the effect of Catechins on
both retinoic acid (RA)-sensitive and -resistant APL cell
lines [34-36], as well as on primary APL cells and on a
murine xenograft APL model. The Catechins-induced
apoptosis of APL cells and expressions of related proteins
(Bcl-2, Bcl-xL, Bax and PML-RARα) were also investi-
gated to explore possible molecular mechanism.
Results
Catechins inhibited cell growth and induced cell
apoptosis in human APL cell lines
Using MTT assay, we determined the effect of Catechins
on various human leukemia cell lines. The IC50 value
(median inhibitory concentration) of Catechins in these
leukemia cells were calculated after 24 hours of treat-
ment. Catechins exerted substantial growth inhibition in
APL cell lines (NB4-R1, NB4-R2 and NB4), Kasumi-1
cells and K562 cells (Figure 1A). However, the sensitivity
of U937 cells to Catechins was relatively lower, with
IC50 higher than 200 μM.
The response curves of NB4-R1, NB4-R2 and NB4 to
Catechins were shown in Figure 1B. Catechins inhibited cell
growth in a time- and dose-dependent manner. To confirm
whether the growth inhibition of Catechins was caused byFigure 1 The effect of Catechins treatment on growth and apoptosis
assay in leukemia cell lines treated with Catechins at 24 h. The IC50 values
inhibition of NB4-R1, NB4-R2 and NB4 cells treated with Catechins for 24 an
50 μM Catechins. (C) Characteristic apoptotic cells were present in NB4-R1,
24 h. (D) Detection of apoptotic cells by Annexin V-FITC/PI double staining
and 48 h. Catechins treatment increased the percentages of Annexin-V+/PI
quadrant). (E) Contribution of nuclear DNA content in NB4-R1, NB4-R2 and
Significantly increased sub-G1 cells were observed. *P < 0.05, **P < 0.01, ***apoptosis, cell morphology and AnnexinV-FITC/PI double
staining were performed. Morphologically, cell apoptosis
was observed at 24 hours of treatment with Catechins,
showing characteristic changes, such as chromatin con-
densation, nuclear fragmentation, and formation of apop-
totic bodies (Figure 1C). The percentage of Annexin
V-positive cells, reflecting those undergoing apoptosis,
was gradually increased during treatment (Figure 1D). Cell
cycle analysis also revealed a time-dependent elevation of
sub-G1 cell content, consistent with Catechins-induced
APL cell apoptosis (Figure 1E).
Catechins-induced apoptosis was associated with
mitochondria damage, ROS production and caspase
activation
The anti-leukemia effect of APL cell lines treated by
ATRA (1 μM), As2O3 (1 μM), EGCG (100 μM), ECG
(100 μM), EGC (100 μM) and Catechins (100 μM) were
further compared. As shown in Figure 2A, Catechins,
more effiently than its main active components, exhib-
ited a significant growth inhibitory effect as observed in
the As2O3 group, indicating that Catechins was equally
effective as As2O3.
NB4 cells were then treated with Catechins, either alone
or combined with pan-caspase inhibitor ZVAD-FMK.
Catechins-induced cell growth inhibition could be signifi-
cantly abrogated by ZVAD-FMK treatment, referring
Catechins as an apoptotic-dependent cell death inducerof human leukemia cell lines. (A) IC50 results obtained from MTT
of NB4-R1, NB4-R2 and NB4 cells were below 125 μM. (B) The growth
d 48 h. Reduced cell viability were detected in APL cell lines from
NB4-R2 and NB4 cells treated with 100 μM or 200 μM Catechins for
in NB4-R1, NB4-R2 and NB4 cells treated with 100 μM Catechins for 24
- cells (lower right quadrant) and Annexin-V+/PI + cells (upper right
NB4 cells treated with 100 μM Catechins for 24 h and 48 h.
P < 0.001 comparing with the untreated cells.
Figure 2 Catechins induced mitochondrial trans-membrane potential collapse, cytochrome C loss and ROS production in NB4 cells. (A)
The inhibitory effect of NB4-R1, NB4-R2 and NB4 cells in response to ATRA (1 μM), As2O3 (1 μM), EGCG (100 μM), ECG (100 μM), EGC (100 μM) and
Catechins (100 μM) treatment for 24 and 48 h. (B) Growth inhibition of NB4 cells was significantly abrogated by pan-caspase inhibitor ZVAD-FMK
(50 μM). **P < 0.01 comparing with the Catechins group. (C) The mitochrondrial trans-membrane potential was decreased in NB4-R1, NB4-R2 and
NB4 cells treated with 100 μM and 200 μM Catechins for 24 h. The numbers below the scatter plots represented the percentage of Rh123 low
cells. (D) The mitochondrial cytochrome c was accordingly decreased in NB4-R1, NB4-R2 and NB4 cells treated with 100 μM and 200 μM
Catechins for 24 h. (E) ROS generation by Catechins in NB4-R1, NB4-R2 and NB4 cells. DCF-derived fluorescence in untreated and in those treated
for 2 h with 200 μM Catechins was shown. *P < 0.05, **P < 0.01, ***P < 0.001 comparing with the untreated cells.
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membrane potential (Δψm) (Figure 2C) and subsequent
decreased mitochondrial cytochrome c (Figure 2D)
were observed in NB4-R1, NB4-R2 and NB4 cells
treated with Catechins in a dose-dependent manner.
To investigate whether ROS level was also affected by
Catechins, we also used flow cytometric analysis with a
cell-permeable dye, H2DCFDA, which is specifically
cleaved to emit a fluorescence wave length in the pres-
ence of ROS. Treatment with 200 μM Catechins for
2 hours resulted in a significant elevation of intracellular
ROS in NB4-R1, NB4-R2 and NB4 cells (Figure 2E).Catechins acted on intrinsic apoptotic pathway through
downregulation of Bcl-xL and induced apoptosis-
independent degradation of PML-RARα oncoprotein
In parallel to Δψm loss, western blot analysis showed that
Catechins significantly induced activation of caspase-3, −8
and −9 in NB4 cells. Correspondingly, PARP was cleaved
to an 89-kDa fragment by Catechins treatment at 24 hours
(Figure 3A). These data suggested that Catechins induced
cell apoptosis through an intrinsic mitochondrial pathway
and was dependent on caspase activation.
Mitochondrial membrane permeability is directly con-
trolled by Bcl-2 family proteins, which are the central
Figure 3 Catechins induced caspase activation, Bcl-xL downregulation, and the degradation of PML-RARα fusion protein in NB4 cells.
(A) Western blot analysis of caspase-3, −8, −9, and PARP in NB4 cells treated with 100 μM and 200 μM Catechins for 24 h. Caspase-3 was
activated with caspase-8 and caspase-9 and PARP cleaved. (B) The expression of Bcl-2, Bcl-xL and Bax protein were determined by Western blot.
Bcl-xL expression was reduced in NB4 cells treated with 100 μM and 200 μM Catechins for 24 h. (C) PML-RARα was decreased upon treatment
with 100 μM and 200 μM Catechins at 12 h and 24 h. (D and E) PML-RARα was not affected by pan-caspase inhibitor ZVAD-FMK (50 μM), but
partially blocked by proteasome inhibitor bortezomib (0.1 μM). Three independent experiments were performed and representative results
were shown.
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Catechins impair the mitochondria through affecting
these Bcl-2 family members, the expression of anti-
apoptotic factor Bcl-2 and Bcl-xL, as well as pro-apoptotic
factor Bax were investigated in NB4 cells at 24 hours of
incubation with Catechins. Bcl-xL expression were de-
creased, while no significant change was detected on Bcl-2
and Bax expression (Figure 3B).
Western blot analysis confirmed that untreated NB4
cells expressed the PML-RARα oncoprotein. Catechins
treatment induced the degradation of PML-RARα at
12 and 24 hours (Figure 3C). Independent on its apop-
totic action, Catechins-mediated degradation of PML-
RARα oncoprotein was not affected by co-treatment
with pan-caspase inhibitor ZVAD-FMK (Figure 3D).
However, the degradation process could be, at least
partially, blocked by proteasome inhibitor bortezomib,
indicating that it was dependent on proteasome pathway
(Figure 3E).Catechins induced apoptosis of leukemia cells from t
(15;17) APL patients and did not affect the proliferation
capacity of normal hematopoietic progenitor cells
Treatment with Catechins significantly inhibited cell
growth and resulted in more than 50% cell inhibition
at 48 hours in primary leukemia cells from three APL
patients with t(15;17) (Figure 4A). Representative morpho-
logical changes of apoptosis were present in the Catechins
group (Figure 4B). Annexin V-PI double staining assay
also revealed increased apoptosis in Catechins-treated
cells, as compared to the untreated cells (Figure 4C).
The ROS production in APL cells treated with 200 μM
Catechins for 2 hours was significantly higher than that
in the untreated cells (Figure 4D). Treatment with
100 μM and 150 μM Catechinsafter 24 hours signifi-
cantly induced the degradation of PML-RARα oncopro-
tein (Figure 4E).
Of note, as determined by MTT assay, proliferation of
CD34+ cells isolated from human cord blood was not
Figure 4 Catechins induced apoptosis in primary APL cells without affecting the proliferation capacity of normal hematopoietic
progenitor cells. (A) Catechins inhibited growth of primary leukemia cells from patients with APL by MTT assay. Cells were treated with 100 μM
and 200 μM Catechins for 24 h and 48 h. (B) Catechins induced apoptosis of primary leukemia cells from three patients by morphological study.
Cells were treated with 100 μM and 200 μM Catechins for 24 h. (C) Apoptosis was evaluated by Annexin V/PI double staining and showed the
fold-increase of apoptotic cells in all three cases. Cells were treated with 100 μM and 200 μM Catechins for 24 and 48 h. **P < 0.01 comparing
with the untreated cells. (D) Intracellular levels of ROS were measured by flow cytometry in all three cases. Cells were treated with 200 μM
Catechins for 2 h. *P < 0.05 comparing with the untreated cells. (E) The PML-RARα oncoprotein was degraded in primary leukemia cells
treated with 100 μM and 150 μM Catechins for 24 h. (F) The proliferation of normal hematopoietic progenitor cells was not inhibited by
Catechins up to 800 μM. CD34+ cells enriched from cord blood samples (n = 3) were cultured in the presence of Catechins at the indicated
concentrations for 72 h. The cell viability was measured by MTT assay.
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72 hours of treatment, suggesting that primary APL cells
responded to Catechins in a similar way as NB4 cells
and Catechins exerted no severe cytotoxic effect on nor-
mal hematopoietic precursors (Figure 4F).
Catechins inhibited tumor growth and induced in situ
leukemia cell apoptosis in a murine xenograft model
We established the human APL model in nude mice
using NB4 cells. NB4 cells (1 × 107) were inoculated sub-
cutaneously into the nude mice (Day 0). The latency of
tumor formation at the site of injection was approxi-
mately 6–8 days. The mice were then treated with Cate-
chins (10 mM) as the only drinking from Day 10 and
tumor volume was measured daily until Day 31. Com-
pared with the untreated group, Catechins significantly
reduced the tumor size (P < 0.01) (Figure 5A). During
treatment, Catechins-treated mice appeared with better
condition than those of the control group. Pathologic
analysis at autopsy revealed no tumor infiltration in any
of the organs (data not shown).
Tumor cell apoptosis was evaluated by TUNEL assay.
Comparing with the control mice, a significantly increased
number of apoptotic cells was observed in the Catechins-treated mice (p < 0.001) (Figure 5B), providing in vivo evi-
dence of Catechins-induced APL cell apoptosis.Discussion
Catechins is the full extracts of the natural green tea
leaves. EGCG is the main component of Catechins and
has been shown with anti-tumor activities in many types
of cancers [15-32]. Here we reported the first time, that
Catechins possessed an anti-proliferative effect on leukemia
cells, especially on t(15;17) leukemia cells. This was ob-
served not only in well-established APL cell lines and
primary tumor samples of APL patients, but also in a
murine xenograft tumor model of t(15;17) leukemia.
Equally effective to targeted agents commonly used in
APL as As2O3, Catechins, with similar bioactivity but
much less expensive than EGCG, could be a potential
candidate to treat APL.
Catechins possesses the anti-leukemic activity mainly
due to the induction of apoptosis, which has been dem-
onstrated by morphological features and increase of
apoptotic cells both in vitro and in vivo. Caspase-3 acti-
vation is essential for leukemia cell apoptosis. In our
study, Catechins generated a cleavage of caspase-3 and
Figure 5 In vivo effect of Catechins on murine models of APL. (A) Catechins decreased the tumor volumes in a murine xenograft model.
Nude mice were received 3 Gy radiation one day before subcutaneous injection with NB4 cells. The treatments began 10 days later including
control diluent (n = 5) and Catechins (10 mM) (n = 5) daily for 21 days. The tumor volumes of control mice and Catechins-treated mice on Day 31
were measured. Catechins significantly reduced the xenograft tumor volumes (*P < 0.05). (B) Apoptotic cells detected by TdT-FragEL™ DNA
Fragmentation Detection kit were calculated. A significantly increased number of apoptotic cells was observed in the Catechins group, comparing
with the untreated group ***P<0.001.
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the hallmark of apoptosis. Bcl-xL, as an important anti-
apoptotic protein of Bcl-2 family [37], was accordingly
reduced by Catechins, further implying that intrinsic
apoptotic pathway was involved in Catechins-induced
apoptosis. This is in consistent with previous study of
EGCG on many solid tumors, such as hepatocellular
carcinoma, chondrosarcoma, and endometrial cancer
[38-42]. Moreover, Catechins also changed the intracel-
lular redox status and regulatedthe mitochondria path-
way through elevating ROS, similar to EGCG [43]. The
intracellular redox status, depending on ROS generation,
is critical in keeping mitochondria stable. Elevation of
intracellular ROS production was also shown during
EGCG-induced apoptosis in tumor cell lines men-
tioned above [38-40]. Therefore, Catechins induced
APL cell apoptosis through intrinsic apoptotic pathway
via Bcl-xL downregulation and ROS induction.
Interestingly, PML-RARα oncoprotein can be directly
targeted by Catechins. In hepatocellular carcinoma, EGCG
lowers the expression of phosphorylated STAT3 protein
and inhibits the expression of multiple genes including
Bcl-xL [44]. In an apoptosis-independent manner,
functional modulation of RARA and PML-RARα by
the peptidyl-prolyl-isomerase Pin1, or the the mitogen-
activated protein kinase, p38α correlates with stabilization/
degradation of PML-RARα via the proteasome pathway
[45,46]. Our data also revealed that Catechins acted on
PML-RARα, at least partially, in a proteasome-dependent
manner. Therefore, PML-RARα oncoprotein may also
represent the target of the Catechins treatment in APL,
although the precise mechanism of action in Catechins-
induced PML-RARα degradation need further investigation.
Our findings not only suggested possible mechanisms
of Catechins in the apoptosis-regulatory pathways in
APL cells, but also provide a model for studying Catechins
in cancer treatment. Since green tea extracts have alreadyentered phase I trials in patients with solid tumors [47-49],
similar clinical trials would be necessary to further evaluate
the anti-leukemic effect of Catechins on acute leukemias.
Conclusions
In summary, our study demonstrated that Catechins ef-
fectively induced apoptosis of APL cells through induc-
tion of intrinsic apoptotic pathway and degradation of
PML-RARα oncoprotein. Catechins may thus be a po-




Catechins (Pharmanex, USA, each capsule contains
EGCG 95 mg, ECG 37 mg, EGC 15 mg), EGCG (Sigma-
ALDRICH, E4143, C22H18O11, MW: 458.37), ECG
(Shanghai Winherb Medical Technology Co., Ltd,
C22H18O10, MW: 442.37) and EGC (Shanghai Winherb
Medical Technology Co., Ltd, C15H14O7, MW: 306.27)
were prepared at the concentration of 10 mM with RPMI
1640 medium (GIBCO-BRL, Grand Island, NY, USA).
Arsenic trioxide (As2O3, Sigma-ALDRICH, A1010, MW:
197.84) was dissolved in RPMI 1640 medium as 5 mM
solution. All-trans-retinoic acid (ATRA, Sigma-ALDRICH)
was dissolved in ethanol as 100 μM solution. Pan-caspase
inhibitor ZVAD-FMK (627610) was from Merck & Co.
Inc. Bortezomib was from Millennium Pharmaceuticals
(Cambridge, MA, USA). The primary antibodies against
β-actin (13E5, #4970), anti-caspase-3 (8G10, #9665),
anti-caspase-8 (D35G2, #4790), anti-caspase-9 Antibody
(#9502), anti-PARP Antibody (#9542), anti-Bcl-2 (D55G8,
#4223), anti-Bax (D2E11, #5023), anti-Bcl-xL (54H6,
#2764) were from Cell Signaling (Beverly, MA, USA).
Mouse monoclonal anti-PML Protein (ab57276) was from
Abcam (Hongkong). The secondary antibody ImmunoPure
Goat Anti-Rabbit IgG (#31460) was from Thermo Scientific
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Immune Biotech Ltd (ImB, CHINA). Chemiluminescence
phototope-horseradish peroxidase kit (WBKLS0100) was
from Millipore (Germany).
Cell lines, cell viability and cell morphology
Human APL leukemia cell lines NB4 (retinoic acid-
sensitive), NB4-R1 and NB4-R2 cells (retinoic acid-
resistant) were kindly provided by Professor Michel
Lanotte at Saint Louis Hospital in France. Acute mye-
loid leukemia cell lines Kasumi-1, K562 and U937 were
available from American Type Culture Collection. Cells
were cultured in RPMI 1640 medium, supplemented with
10% heat-inactivated fetal bovine serum (GIBCO-BRL),
100 U/mL penicillin and 100 mg/mL streptomycin
(GIBCO-BRL), in 5%CO2-95% air humidified atmos-
phere at 37°C. Fresh leukemia cells from the bone mar-
row of three APL patients were enriched by Ficoll
separation. The diagnosis was established on the basis
of morphological examination, presence of t(15;17) by
cytogenetic study and PML-RARα fusion gene by molecu-
lar analysis. CD34+ cells were purified from human cord
blood by density gradient centrifugation. Informed con-
sent was obtained according to institutional guidelines.
Cell viability was assessed by triplicate counting of try-
pan blue dye-excluding cells under light microscopy.
Cell morphology was evaluated by Wright’s staining of
cells prepared by cytospin centrifugation.
MTT reduction assay
A total of 5 × 104 cells per well were seeded in a 96-well
plate, and treated with Catechins at concentrations of
25, 50, 100, 200 or 400 μM for different time (24 h, 48 h
or 72 h). After treatment, 0.1 mg MTT was added to
each well. The samples were incubated for 4 hours and
the absorbance (optical density, OD value) was mea-
sured at 490 nm by spectrophotometry. Calculation of
the cell growth inhibition rate at different concentrations
is done by comparing it against the growth rate of un-
treated control group. Inhibition rate = [1 - OD value of
treated cell/OD value of control cell] × 100%.
Flow cytometric assays for Annexin-V/PI, nuclear DNA
contentdistribution, mitochondrial trans-membrane
potentials, mitochondrial cytochrome c, and reactive
oxygen species (ROS) detection
A total of 2 × 105 cells was analyzed using an Annexin
V-FITC/PI apoptosis detection kit II (BD Pharmingen™,
Franklin Lakes, NJ, USA) according to manufacturer’s
instructions. To assess the distribution of nuclear DNA
content, cells were collected, washed in PBS and fixed
overnight in 75% ethanol at −20°C, treated with 1%
RNase A for at least 15 min at 37°C, and stained with 50
μg/ml PI. For mitochondrial trans-membrane potentialassessment, 1 × 106 cells were washed twice with PBS,
incubated with 10 μg/mL of Rh123 for 30 min at 37°C,
and stained with 50 μg/mL of PI. Mitochondrial cyto-
chrome c was measured by FlowCellect™ cytochrome c
kit (Millipore) according to manufacturer’s protocols. To
measure ROS levels, 5 × 105 cells were washed with
RPMI1640 and incubated with 5 μM DCFH-DA for
30 min at 37°C. The fluorescent intensity was measured
by flow cytometry (Becton Dickinson, San Jose, CA,
USA). All experiments were performed in triplicate and
data were collected, stored, and analyzed by Lysis 11
software (Becton Dickinson).
Western blot analysis
Western blot analysis was performed according to stand-
ard protocols. Approximately 5 × 106 cells were harvested
and incubated in 100 μL lysis buffer [50 mM Tris
(pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% deoxycho-
late, 0.1% SDS)] to prepare total protein samples. Equal
amounts of protein (20 μg) were separated by SDS-PAGE
on 10% gels and transferred on to PVDF membrane
(Millipore), and blocked with 5% non-fat dried milk in
TBST [phosphate-buffered saline-0.05% Tween] at room
temperature for 60 min. The membranes were subjected
to immunoblot analyses with appropriate primary anti-
body followed by horseradish peroxidase-linked secondary
antibody. The immunocomplexes were visualized using
chemiluminescence phototype-horseradish peroxidase kit.
Terminal deoxytransferase-catalyzed DNA nick-end
labeling (TUNEL) assay
In situ tumor cell apoptosis was performed on deparaffi-
nized 5 μm thick sections using TdT-FragEL™ DNA Frag-
mentation Detection Kit (Merck, Germany) according to
the manufacturer’s recommendation. For quantification,
three different fields were counted under light microscopy
and at least 500 cells were enumerated in each field. All
experiments were performed in triplicate.
APL murine model
Murine xenograft APL model was established by NB4
cells inoculation in nude mice. Briefly, mice were pre-
treated with 3 Gy of total body irradiation, which is a sub-
lethal dose that was expected to enhance the acceptance
of xenografts. Subsequently, NB4 cells (1 × 107) were inoc-
ulated subcutaneously into the right flank of nude mice
(male, 5–6 weeks of age). Inoculated NB4 cells formed
subcutaneous tumors at the injection site from 6–8 days.
Ten days after cell inoculation, mice were randomly di-
vided into two groups, and received water (n = 5) or
Catechins (10 mM, n = 5) as the sole drinking treated
for 21 days. Tumor volumes were calculated by the for-
mula: 0.5 × a × b2 in millimeters, where ‘a’ is the length
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maldehyde and further embedded in paraffin.
Statistical analysis
All the results were expressed as the mean ± S.D. and
determined using t-test to compare variance. Survival
functions were estimated using the Kaplan-Meier method
and compared by the log-rank test. P value < 0.05 were
considered statistically significant. All statistical analyses
were evaluated using the SPSS for Windows, Version 18.0.
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